4 research outputs found
Resistance patterns of Mycobacterium tuberculosis isolated in Mexico's West
No full textBackground: The problem of multidrug resistant M, tuberculosis (MDR TB) has increased in recent years around the world. Objetive: To analyse the evolution of resistance patteras of M. tuberculosis. Methods: Cultures of M. tuberculosis isolated from patients of two terciary care hospitals of Guadalajara, México were analyzed. Susceptibility tests were earned out by the Canetti method. Results: The annual resistance percents of 262 cultures was: 1993 1994 1995 1996 Total (a=23) (a=26) (n=64) (n=149) (=262) Isomazid 74 77 53 78 71 Rifampin 43 42 41 40 41 Pyrazinamide 22 58 67 52 54 Ethambutol 65 62 47 77 53 Streptomycin 22 46 75 56 57 Ethionamide 22 27 50 49 45 Para-aminosalicyhc-acid(PAS) 30 46 41 45 43 Ciprofloxadn - 12 30 17 20 Ofloxacin - 15 30 39 34 MDR TB (isoniazid and rifampin) 43 27 31 36 31 Conclusions: The primary drugs resistance is high, the resistance to pyrazinamide, streptomycin, ethionamide and PAS has been increasing
Resistance patterns of Mycobacterium tuberculosis isolated in Mexico's West
No full textBackground: The problem of multidrug resistant M, tuberculosis (MDR TB) has increased in recent years around the world. Objetive: To analyse the evolution of resistance patteras of M. tuberculosis. Methods: Cultures of M. tuberculosis isolated from patients of two terciary care hospitals of Guadalajara, México were analyzed. Susceptibility tests were earned out by the Canetti method. Results: The annual resistance percents of 262 cultures was: 1993 1994 1995 1996 Total (a=23) (a=26) (n=64) (n=149) (=262) Isomazid 74 77 53 78 71 Rifampin 43 42 41 40 41 Pyrazinamide 22 58 67 52 54 Ethambutol 65 62 47 77 53 Streptomycin 22 46 75 56 57 Ethionamide 22 27 50 49 45 Para-aminosalicyhc-acid(PAS) 30 46 41 45 43 Ciprofloxadn - 12 30 17 20 Ofloxacin - 15 30 39 34 MDR TB (isoniazid and rifampin) 43 27 31 36 31 Conclusions: The primary drugs resistance is high, the resistance to pyrazinamide, streptomycin, ethionamide and PAS has been increasing
ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina11This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999.When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O’Rourke RA, Schafer WP, Williams SV. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092–197.This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). Reprints of this document are available by calling 1-800-253-4636 or writing the American College of Cardiology, Educational Services, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint number 71-0166. To obtain a reprint of the Executive Summary and Recommendations published in the June 1, 1999 issue of Circulation, ask for reprint number 71-0167. To purchase bulk reprints (specify version and reprint number): Up to 999 copies call 1-800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies call 214-706-1466, fax 214-691-6342, or e-mail [email protected]
No full text
